Schizophrenia: Genetics, prevention and rehabilitation;Schizofrenia: Genetica, prevenzione e riabilitazione

Italian Journal of Psychopathology

Volumn 14, Issue 2, 2008, Pages 108-133

  Olgiati, P ^a   Lorenzi, C ^b   Marino, E ^b   Pirovano, A ^b   De Ronchi, D ^a   Serretti, Alessandro ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

Endophenotypes; Genetics; Riabilitazione; Schizophrenia

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; CATECHOL METHYLTRANSFERASE; DISRUPTED IN SCHIZOPHRENIA 1; DYSBINDIN; GENE PRODUCT; METABOTROPIC RECEPTOR 3; METHIONINE; NEU DIFFERENTIATION FACTOR; PROTEIN KINASE B; UNCLASSIFIED DRUG; VALINE;

ALLELE; ARTICLE; COGNITION; ENVIRONMENTAL FACTOR; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; HUMAN; MULTIFACTORIAL GENETIC DISORDER; PHENOTYPE; PREFRONTAL CORTEX; RISK FACTOR; SCHIZOPHRENIA; WORKING MEMORY;

EID: 57049144266     PISSN: 15921107     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (316)

1. Zivanovic O, Borisev L. Genetic factors in the onset of schizophrenia. Med Pregl 1999;52:25-8.
2. Franzos M, Bhatia T, Wood J, Nimgaonkar V, Deshpande S. Gender parity in procreation among indians with schizophrenia. In: Barden N, De Lisi L, Gill M, Kelsoe J, editors. Proceedings of the XI World Congress of Psychiatric Genetics, Quebec City 2003, p. 165.
3. Tsuang MT, Winokur G, Crowe RR. Morbidity risks of schizophrenia and affective disorders among first degree relatives of patients with schizophrenia, mania, depression and surgical conditions. Br J Psychiatry 1980;137:497-504.
4. Cardno AG, Marshall EJ, Coid B, MacDonald AM, Ribchester TR, Davies NJ, et al. Heritability estimates for psychotic disorders: the Maudsley twin psychosis series. Arch Gen Psychiatry 1999;56:162-8.
5. Sullivan PF, Kendler KS, Neale MC. Schizophrenia as a complex trait: evidence from a meta-analysis of twin studies. Arch Gen Psychiatry 2003;60:1187-92.
6. Portin P, Alanen YO. A critical review of genetic studies of schizophrenia. I. Epidemiological and brain studies. Acta Psychiatr Scand 1997;95:1-5.
7. McDonald C, Murray RM. Early and late environmental risk factors for schizophrenia. Brain Res Brain Res Rev 2000;31:130-7.
8. Tienari P, Wynne LC, Moring J, Lahti I, Naarala M, Sorri A, et al. The Finnish adoptive family study of schizophrenia. Implications for family research. Br J Psychiatry 1994;(Suppl):20-6.
9. Gottesman, II, Gould TD. The endophenotype concept in psychiatry: etymology and strategic intentions. Am J Psychiatry 2003;160:636-45.
10. Green MF. Cognitive impairment and functional outcome in schizophrenia and bipolar disorder. J Clin Psychiatry 2006;67(Suppl 9):3-8.
11. Thaker GK. Schizophrenia endophenotypes as treatment targets. Expert Opin Ther Targets 2007;11:1189-206.
12. Thomson G, Esposito MS. The genetics of complex diseases. Trends Cell Biol 1999;9:M17-20.
13. Burmeister M. Basic concepts in the study of diseases with complex genetics. Biol Psychiatry 1999;45:522-32.
14. Faraone S, Tsuang M, Tsuang D. Genetics of mental disorders. New York: The Guilford Press 1999.
15. Collins FS, Guyer MS, Charkravarti A. Variations on a theme: cataloging human DNA sequence variation. Science 1997;278:1580-1.
16. Schork NJ, Fallin D, Lanchbury JS. Single nucleotide polymorphisms and the future of genetic epidemiology. Clin Genet 2000;58:250-64.
17. Wang DG, Fan JB, Siao CJ, Berno A, Young P, Sapolsky R, et al. Large-scale identification, mapping, and genotyping of single-nucleotide polymorphisms in the human genome. Science 1998; 280:1077-82.
18. Botstein D, Risch N. Discovering genotypes underlying human phenotypes: past successes for mendelian disease, future approaches for complex disease. Nat Genet 2003;33(Suppl):228-37.
19. Levinson DF, Levinson MD, Segurado R, Lewis CM. Genome scan meta-analysis of schizophrenia and bipolar disorder, part I: methods and power analysis. Am J Hum Genet 2003;73:17-33.
20. Lewis CM, Levinson DF, Wise LH, De Lisi LE, Straub RE, Hovatta I, et al. Genome scan meta-analysis of schizophrenia and bipolar disorder, part II: schizophrenia. Am J Hum Genet 2003;73:17-33.
21. Segurado R, Detera-Wadleigh SD, Levinson DF, Lewis CM, Gill M, Nurnberger JI Jr, et al. Genome scan meta-analysis of schizophrenia and bipolar disorder, part III: bipolar disorder. Am J Hum Genet 2003;73:34-48.
22. Wong AH, Van Tol HH. Schizophrenia: from phenomenology to neurobiology. Neurosci Biobehav Rev 2003;27:269-306.
23. Park N, Juo S, Liu J, Loth J, Lilliston B, Nee J, et al. Linkage analysis of psychosis in bipolar pedigrees suggests novel putative loci for bipolar disorder and shared susceptibility loci for bipolar disorder and schizophrenia. In: Barden N, De Lisi L, Gill M, Kelsoe J, editors. Proceedings of the XI World Congress of Psychiatric Genetics, Quebec City 2003, p. 43.
24. Lander E, Kruglyak L. Genetic dissection of complex traits: guidelines for interpreting and reporting linkage results. Nat Gen 1995;11:241-7.
25. Pickar D, Rubinow K. Pharmacogenomics of psychiatric disorders. Trends Pharmacol Sci 2001;22:75-83.
26. Prasad S, Semwal P, Deshpande S, Bhatia T, Nimgaonkar VL, Thelma BK. Molecular genetics of schizophrenia: past, present and future. J Biosci 2002;27(Suppl 1):35-52.
27. Nurnberger JI Jr, Blehar MC, Kaufmann CA, York-Cooler C, Simpson SG, Harkavy-Friedman J, et al. Diagnostic interview for genetic studies. Rationale, unique features, and training. NIMH genetics initiative. Arch Gen Psychiatry 1994;51:849-59.
28. Tsuang MT, Faraone SV, Fleming JA. Familial transmission of major affective disorders. Is there evidence supporting the distinction between unipolar and bipolar disorders? Br J Psychiatry 1985;146:268-71.
29. Gottesman, II, Gould TD. The endophenotype concept in psychiatry: etymology and strategic intentions. Am J Psychiatry 2003;160:636-45.
30. Fioravanti M, Carlone O, Vitale B, Cinti M, Clare L. A meta-analysis of cognitive deficits in adults with a diagnosis of schizophrenia. Neuropsychol Rev 2005;15:73-95.
31. Sitskoorn M, Aleman A, Ebisch S, Appels M, Kahn R. Cognitive deficits in relatives of patients with schizophrenia: a meta-analysis. Schizophr Res 2004;71:285-95.
32. Saperstein AM, Fuller RL, Avila MT, Adami H, McMahon RP, Thaker GK, et al. Spatial working memory as a cognitive endophenotype of schizophrenia: assessing risk for pathophysiological dysfunction. Schizophr Bull 2006;32:498-506.
33. Diwadkar V, Montrose D, Dworakowski D, Sweeney J, Keshavan M. Genetically predisposed offspring with schizotypal features: an ultra high-risk group for schizophrenia? Prog Neuropsychopharmacol Biol Psychiatry 2006;30:230-8.
34. Grossman MH, Littrell J, Weinstein R, Punnett HH, Emanuel BS, Budarf M. The gene for human catechol-O-methyltransferase (COMT) maps to 22pter22q11.1. Cytogenet Cell Genet 1991;58:2048.
35. Polymeropoulos MH, Coon H, Byerley W, Gershon ES, Goldin L, Crow TJ, et al. Search for a schizophrenia susceptibility locus on human chromosome 22. Am J Med Genet 1994;54:93-9.
36. Vallada HP, Gill M, Sham P, Lim LC, Nanko S, Asherson P, et al. Linkage studies on chromosome 22 in familial schizophrenia. Am J Med Genet 1995;60:139-46.
37. Lachman HM, Papolos DF, Saito T, Yu YM, Szumlanski CL, Weinshilboum RM. Human catechol-O-methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders. Pharmacogenetics 1996;6:243-50.
38. Glatt SJ, Faraone SV, Tsuang MT. Association between a functional catechol O-methyltransferase gene polymorphism and schizophrenia: meta-analysis of case-control and family-based studies. Am J Psychiatry 2003;160:469-76.
39. Egan MF, Goldberg TE, Kolachana BS, Callicott JH, Mazzanti CM, Straub RE, et al. Effect of COMT Val108/158 Met genotype on frontal lobe function and risk for schizophrenia. Proc Natl Acad Sci USA 2001;98:6917-22.
40. Barnett J, Jones P, Robbins T, Müller U. Effects of the catechol-O-methyltransferase Val158Met polymorphism on executive function: a meta-analysis of the Wisconsin Card Sort Test in schizophrenia and healthy controls. Biol Psychiatry 2007;12:502-9.
41. Diaz-Asper C, Goldberg T, Kolachana B, Straub R, Egan M, Weinberger D. Genetic variation in Catechol-O-methyltransferase: effects on working memory in schizophrenic patients, their siblings, and healthy controls. Biol Psychiatry 2008;63:72-9.
42. Goldberg TE, Weinberger DR. Genes and the parsing of cognitive processes. Trends Cogn Sci 2004;8:325-35.
43. Falls DL. Neuregulins: functions, forms, and signaling strategies. Exp Cell Res 2003;284:14-30.
44. Bjarnadottir M, Misner DL, Haverfield-Gross S, Bruun S, Helgason VG, Stefansson H, et al. Neuregulin 1 (NRG1) signaling through Fyn modulates NMDA receptor phosphorylation: differential synaptic function in NRG 1+/- knock-outs compared with wild-type mice. J Neurosci 2007;27:4519-29.
45. Corfas G, Roy K, Buxbaum JD. Neuregulin 1-erbB signaling and the molecular/cellular basis of schizophrenia. Nat Neurosci 2004; 7:575-80.
46. O'Tuathaigh CM, Babovic D, O'Meara G, Clifford JJ, Croke DT, Waddington JL. Susceptibility genes for schizophrenia: characterisation of mutant mouse models at the level of phenotypic behaviour. Neurosci Biobehav Rev 2007;31:60-78.
47. Stefanis NC, Trikalinos TA, Avramopoulos D, Smyrnis N, Evdokimidis I, Ntzani EE, et al. Impact of schizophrenia candidate genes on schizotypy and cognitive endophenotypes at the population level. Biol Psychiatry 2007b;62:784-92.
48. Takahashi M, Shirakawa O, Toyooka K, Kitamura N, Hashimoto T, Maeda K, et al. Abnormal expression of brain-derived neurotrophic factor and its receptor in the corticolimbic system of schizophrenic patients. Mol Psychiatry 2000;5:293-300.
49. Weickert CS, Hyde TM, Lipska BK, Herman MM, Weinberger DR, Kleinman JE. Reduced brain-derived neurotrophic factor in prefrontal cortex of patients with schizophrenia. Mol Psychiatry 2003;8:592-610.
50. Angelucci F, Mathe AA, Aloe L. Brain-derived neurotrophic factor and tyrosine kinase receptor TrkB in rat brain are significantly altered after haloperidol and risperidone admimistration. J Neurosci Res 2000;60:783-94.
51. Lipska BK, Khaing ZZ, Weickert CS, Weinberger DR. BDNF mRNA expression in rat hippocampus and prefrontal cortex: effects of neonatal ventral hippocampal damage and antipsychotic drugs. Eur J Neurosci 2001;14:135-44.
52. Rybakowski JK, Borkowska A, Skibinska M, Szczepankiewicz A, Kapelski P, Leszczynska-Rodziewicz A, et al. Prefrontal cognition in schizophrenia and bipolar illness in relation to Va166Met polymorphism of the brain-derived neurotrophic factor gene. Psychiatry Clin Neurosci 2006;60:70-6.
53. Ho BC, Milev P, O'Leary DS, Librant A, Andreasen NC, Wassink TH. Cognitive and magnetic resonance imaging brain morphometric correlates of brain-derived neurotrophic factor Va166Met gene polymorphism in patients with schizophrenia and healthy volunteers. Arch Gen Psychiatry 2006;63:731-40.
54. James R, Adams RR, Christie S, Buchanan SR, Porteous DJ, Millar JK. Disrupted in Schizophrenia 1 (DISC1) is a multicompartmentalized protein that predominantly localizes to mitochondria. Mol Cell Neurosci 2004;26:112-22.
55. Roberts RC. Schizophrenia in translation: disrupted in schizophrenia (DISC 1): integrating clinical and basic findings. Schizophr Bull 2007;33:11-5.
56. Bellon A. New genes associated with schizophrenia in neurite formation: a review of cell culture experiments. Mol Psychiatry 2007;12:620-9.
57. Duan X, Chang JH, Ge S, Faulkner RL, Kim JY, Kitabatake Y, et al. Disrupted-in-schizophrenia 1 regulates integration of newly generated neurons in the adult brain. Cell 2007;130:1146-58.
58. Liu YL, Fann CS, Liu CM, Chen WJ, Wu JY, Hung SI, et al. A single nucleotide polymorphism fine mapping study of chromosome 1q42.1 reveals the vulnerability genes for schizophrenia, GNPAT and DISC1: association with impairment of sustained attention. Biol Psychiatry 2006b;60:554-62.
59. Hennah W, Tuulio-Henriksson A, Paunio T, Ekelund J, Varilo T, Partonen T, et al. A haplotype within the DISC1 gene is associated with visual memory functions in families with a high density of schizophrenia. Mol Psychiatry 2005;10:1097-103.
60. Benson MA, Newey SE, Martin-Rendon E, Hawkes R, Blake DJ. Dysbindin, a novel coiled-coil-containing protein that interacts with the dystrobrevins in muscle and brain. J Biol Chem 2001;276:24232-41.
61. Numakawa T, Yagasaki Y, Ishimoto T, Okada T, Suzuki T, Iwata N, et al. Evidence of novel neuronal functions of dysbindin, a susceptibility gene for schizophrenia. Hum Mol Genet 2004;13:2699-708.
62. Talbot K, Eidem WL, Tinsley CL, Benson MA, Thompson EW, Smith RJ, et al. Dysbindin-1 is reduced in intrinsic, glutamatergic terminals of the hippocampal formation in schizophrenia. J Clin Invest 2004;113:1353-63.
63. Weickert CS, Straub RE, McClintock BW, Matsumoto M, Hashimoto R, Hyde TM, et al. Human dysbindin (DTNBP1) gene expression in normal brain and in schizophrenic prefrontal cortex and midbrain. Arch Gen Psychiatry 2004;61:544-55.
64. Bray NJ, Preece A, Williams NM, Moskvina V, Buckland PR, Owen MJ, et al. Haplotypes at the dystrobrevin binding protein 1 (DTNBP1) gene locus mediate risk for schizophrenia through reduced DTNBP1 expression. Hum Mol Genet 2005;14:1947-54.
65. Donohoe G, Morris DW, Clarke S, McGhee KA, Schwaiger S, Nangle JM, et al. Variance in neurocognitive performance is associated with dysbindin-1 in schizophrenia: a preliminary study. Neuropsychologia 2007;45:454-8.
66. Donohoe G, Morris DW, De Sanctis P, Magno E, Montesi JL, Garavan HP, et al. Early Visual Processing Deficits in Dysbindin-Associated Schizophrenia. Biol Psychiatry 2008;63:484-9.
67. Burdick KF, Lencz T, Funke B, Finn CT, Szeszko PR, Kane JM, et al. Genetic variation in DTNBP1 influences general cognitive ability. Hum Mol Genet 2006;15:1563-8.
68. Coyle JT. The glutamatergic dysfunction hypothesis for schizophrenia. Harv Rev Psychiatry 1996;3:241-53.
69. Clark M, Johnson BG, Wright RA, Monn JA, Schoepp DD. Effects of the mGlu2/3 receptor agonist LY379268 on motor activity in phencyclidine-sensitized rats. Pharmacol Biochem Behav 2002; 73:339-46.
70. Patil ST, Zhang L, Martenyi F, Lowe SL, Jackson KA, Andreev BV, et al. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized phase 2 clinical trial. Nat Med 2007;13:1102-7.
71. Egan MF, Straub RE, Goldberg TE, Yakub I, Callicott JH, Hariri AR, et al. Variation in GRM3 affects cognition, prefrontal glutamate, and risk for schizophrenia. Proc Natl Acad Sci USA 2004;101:12604-9.
72. Erwin RJ, Turetsky BI, Moberg P, Gur RC, Gur RE. P50 abnormalities in schizophrenia: relationship to clinical and neuropsychological indices of attention. Schizophr Res 1998;33:157-67.
73. Shajahan PM, O'Carroll RE, Glabus MF, Ebmeier KP, Blackwood DH. Correlation of auditory 'oddball' P300 with verbal memory deficits in schizophrenia. Psychol Med 1997;27:579-86.
74. Souza VB, Muir WJ, Walker MT, Glabus MF, Roxborough HM, Sharp CW, et al. Auditory P300 event-related potentials and neuropsychological performance in schizophrenia and bipolar affective disorder. Biol Psychiatry 1995;37:300-10.
75. Patterson JV, Hetrick WP, Boutros NN, Jin Y, Sandman C, Stern H, et al. P50 sensory gating ratios in schizophrenics and controls: a review and data analysis. Psychiatry Res 2008;158:226-47.
76. Turetsky BI, Calkins ME, Light GA, Olincy A, Radant AD, Swerdlow NR. Neurophysiological endophenotypes of schizophrenia: the viability of selected candidate measures. Schizophr Bull 2007;33:69-94.
77. Light GA, Geyer MA, Clementz BA, Cadenhead KS, Braff DL. Normal P50 suppression in schizophrenia patients treated with atypical antipsychotic medications. Am J Psychiatry 2000;157:767-71.
78. Umbricht D, Javitt D, Novak G, Bates J, Pollack S, Lieberman J, et al. Effects of clozapine on auditory event-related potentials in schizophrenia. Biol Psychiatry 1998;44:716-25.
79. Adler LE, Hoffer LD, Wiser A, Freedman R. Normalization of auditory physiology by cigarette smoking in schizophrenic patients. Am J Psychiatry 1993;150:1856-61.
80. Adler LE, Hoffer LJ, Griffith J, Waldo MC, Freedman R. Normalization by nicotine of deficient auditory sensory gating in the relatives of schizophrenics. Biol Psychiatry 1992;32:607-16.
81. Freedman R, Olincy A, Ross RG, Waldo MC, Stevens KE, Adler LE, et al. The genetics of sensory gating deficits in schizophrenia. Curr Psychiatry Rep 2003;5:155-61.
82. Houy E, Raux G, Thibaut F, Belmont A, Demily C, Allio G, et al. The promoter- 194 C polymorphism of the nicotinic alpha-7 receptor gene has a protective effect against the P50 sensory gating deficit. Mol Psychiatry 2004;9:320-2.
83. Martin LF, Leonard S, Hall MH, Tregellas JR, Freedman R, Olincy A. Sensory gating and alpha-7 nicotinic receptor gene allelic variants in schizoaffective disorder, bipolar type. Am J Med Genet B Neuropsychiatr Genet 2007;144:611-4.
84. Lu BY, Martin KE, Edgar JC, Smith AK, Lewis SF, Escamilla MA, et al. Effect of catechol O-methyltransferase val(158)met polymorphism on the p50 gating endophenotype in schizophrenia. Biol Psychiatry 2007;62:822-5.
85. Gallinat J, Bajbouj M, Sander T, Schlattmann P, Xu K, Ferro EF, et al. Association of the G 1947A COMT (Val(108/158)Met) gene polymorphism with prefrontal P300 during information processing. Biol Psychiatry 2003;54:40-8.
86. Golimbet V, Gritsenko I, Alfimova M, Lebedeva I, Lezheiko T, Abramova L, et al. Association study of COMT gene Val158Met polymorphism with auditory P300 and performance on neurocognitive tests in patients with schizophrenia and their relatives. World J Biol Psychiatry 2006;7:238-45.
87. Blackwood DH, Muir WJ. Clinical phenotypes associated with DISC1, a candidate gene for schizophrenia. Neurotox Res 2004;6:35-41.
88. Hennah W, Thomson P, Peltonen L, Porteous D. Genes and schizophrenia: beyond schizophrenia: the role of DISC1 in major mental illness. Schizophr Bull 2006;32:409-16.
89. Meehl P. Schizotaxia, schizotypy, schizophrenia. Am Psychol 1962;17:827-38.
90. Stone W, Faraone S, Seidman L, Green A, Wojcik J, Tsuang M. Concurrent validation of schizotaxia: a pilot study. Biol Psychiatry 2001;50:434-40.
91. Horan WP, Blanchard JJ, Gangestad SW, Kwapil TR. The psychometric detection of schizotypy: do putative schizotypy indicators identify the same latent class? J Abnorm Psychol 2004;113:339-57.
92. Lenzenweger MF. Explorations in schizotypy and the psychometric high-risk paradigm. Prog Exp Pers Psychopathol Res 1993;16:66-116.
93. Chen WJ, Hsiao CK, Lin CC. Schizotypy in community samples: the three-factor structure and correlation with sustained attention. J Abnorm Psychol 1997;106:649-54.
94. Vollema MG, van den Bosch RJ. The multidimensionality of schizotypy. Schizophr Bull 1995;21:19-31.
95. Avramopoulos D, Stefanis NC, Hantoumi I, Smyrnis N, Evdokimidis I, Stefanis CN. Higher scores of self reported schizotypy in healthy young males carrying the COMT high activity allele. Mol Psychiatry 2002;7:706-11.
96. Schurhoff F, Szoke A, Chevalier F, Roy I, Meary A, Bellivier F, et al. Schizotypal dimensions: an intermediate phenotype associated with the COMT high activity allele. Am J Med Genet B Neuropsychiatr Genet 2007;144:64-8.
97. Stefanis NC, Henquet C, Avramopoulos D, Smyrnis N, Evdokimidis I, Myin-Germeys I, et al. COMT Val158Met moderation of stress-induced psychosis. Psychol Med 2007;37:1 651-6.
98. Ma X, Sun J, Yao J, Wang Q, Hu X, Deng W, et al. A quantitative association study between schizotypal traits and COMT, PRODH and BDNF genes in a healthy Chinese population. Psychiatry Res 2007;153:7-15.
99. Tsuang MT, Stone WS, Faraone SV. Genes, environment and schizophrenia. Br J Psychiatry 2001;40(Suppl): s18-24.
100. McGuffin P, Asherson P, Owen M, Farmer A. The strength of the genetic effect. Is there room for an environmental influence in the aetiology of schizophrenia? Br J Psychiatry 1994;164:593-9.
101. Boog G. Obstetrical complications and further schizophrenia of the infant: a new medicolegal threat to the obstetrician? J Gynecol Obstet Biol Reprod (Paris) 2003;32:720-7.
102. Clarke MC, Harley M, Cannon M. The role of obstetric events in schizophrenia. Schizophr Bull 2006;32:3-8.
103. Byrne M, Agerbo E, Bennedsen B, Eaton WW, Mortensen PB. Obstetric conditions and risk of first admission with schizophrenia: a Danish national register based study. Schizophr Res 2007;97:51-9.
104. Dalman C, Thomas HV, David AS, Gentz J, Lewis G, Allebeck P. Signs of asphyxia at birth and risk of schizophrenia. Population-based case-control study. Br J Psychiatry 2001;179:403-8.
105. Preti A, Cardascia L, Zen T, Marchetti M, Favaretto G, Miotto P. Risk for obstetric complications and schizophrenia. Psychiatry Res 2000;96:127-39.
106. Cannon TD, van Erp TG, Rosso IM, Huttunen M, Lonnqvist J, Pirkola T, et al. Fetal hypoxia and structural brain abnormalities in schizophrenic patients, their siblings, and controls. Arch Gen Psychiatry 2002;59:35-41.
107. Schmidt-Kastner R, van Os J, Schmitz C. Gene regulation by hypoxia and the neurodevelopmental origin of schizophrenia. Schizophr Res 2006;84:253-71.
108. Nadri C, Belmaker RH, Agam G. Oxygen restriction of neonate rats elevates neuregulin-1alpha isoform levels: possible relationship to schizophrenia. Neurochem Int 2007;51:447-50.
109. Nicodemus KK, Marenco S, Batten AJ, Vakkalanka R, Egan MF, Straub RE, et al. Serious obstetric complications interact with hypoxia-regulated/ vascular-expression genes to influence schizophrenia risk. Mol Psychiatry 2008 Jan 15.
110. Chen CH, Chiu YL, Shaw CK, Tsai MT, Hwang AL, Hsiao KJ. Detection of Borna disease virus RNA from peripheral blood cells in schizophrenic patients and mental health workers. Mol Psychiatry 1999;4:566-71.
111. Iwahashi K, Watanabe M, Nakamura K, Suwaki H, Nakaya T, Nakamura Y, et al. Clinical investigation of the relationship between Borna disease virus (BDV) infection and schizophrenia in 67 patients in Japan. Acta Psychiatr Scand 1997;96:412-5.
112. Miranda HC, Nunes SO, Calvo ES, Suzart S, Itano EN, Watanabe MA. Detection of Borna disease virus p24 RNA in peripheral blood cells from Brazilian mood and psychotic disorder patients. J Affect Disord 2006;90:43-7.
113. Taieb O, Baleyte JM, Mazet P, Fillet AM. Borna disease virus and psychiatry. Eur Psychiatry 2001;16:3-10.
114. Waltrip RW 2nd, Buchanan RW, Summerfelt A, Breier A, Carpenter WT Jr, Bryant NL, et al. Borna disease virus and schizophrenia. Psychiatry Res 1995;56:33-44.
115. Yamaguchi K, Sawada T, Naraki T, Igata-Yi R, Shiraki H, Horii Y, et al. Detection of Borna disease virus-reactive antibodies from patients with psychiatric disorders and from horses by electrochemiluminescence immunoassay. Clin Diagn Lab Immunol 1999;6:696-700.
116. Sansom C. A role for Borna disease virus in schizophrenia? Mol Med Today 2000;6:295.
117. Adams W, Kendell RE, Hare EH, Munk-Jorgensen P. Epidemiological evidence that maternal influenza contributes to the aetiology of schizophrenia. An analysis of Scottish, English, and Danish data. Br J Psychiatry 1993;163:522-34.
118. McGrath JJ, Pemberton MR, Welham JL, Murray RM. Schizophrenia and the influenza epidemics of 1954, 1957 and 1959: a southern hemisphere study. Schizophr Res 1994;14:1-8.
119. Sham PC, O'Callaghan E, Takei N, Murray GK, Hare EH, Murray RM. Schizophrenia following pre-natal exposure to influenza epidemics between 1939 and 1960. Br J Psychiatry 1992;160:461-6.
120. Castle D, Gill M. Maternal viral infection and schizophrenia. Br J Psychiatry 1992;161:273-4.
121. Limosin F, Rouillon F, Payan C, Cohen JM, Strub N. Prenatal exposure to influenza as a risk factor for adult schizophrenia. Acta Psychiatr Scand 2003;107:331-5.
122. Buka SL, Cannon TD, Torrey EF, Yolken RH; Collaborative Study Group on the Perinatal Origins of Severe Psychiatric Disorders. Maternal exposure to herpes simplex virus and risk of psychosis among adult offspring. Biol Psychiatry 2008;63:809-15.
123. Yolken R. Viruses and schizophrenia: a focus on Herpes Simplex virus. Herpes 2004;11 (Suppl 2):83A-8A.
124. Beraki S, Aronsson F, Karlsson H, Ogren SO, Kristensson K. Influenza A virus infection causes alterations in expression of synaptic regulatory genes combined with changes in cognitive and emotional behaviors in mice. Mol Psychiatry 2005;10:299-308.
125. Kim JJ, Shirts BH, Dayal M, Bacanu SA, Wood J, Xie W, et al. Are exposure to cytomegalovirus and genetic variation on chromosome 6p joint risk factors for schizophrenia? Ann Med 2007;39:145-53.
126. Buhler B, Hambrecht M, Loffler W, Van der Heiden W, Hafner H. Precipitation and determination of the onset and course of schizophrenia by substance abuse - a retrospective and prospective study of 232 population-based first illness episodes. Schizophr Res 2002; 54:243-51.
127. Fowler IL, Carr VJ, Carter NT, Lewin TJ. Patterns of current and lifetime substance use in schizophrenia. Schizophr Bull 1998;24:443-55.
128. Rabinowitz J, Bromet EJ, Lavelle J, Carlson G, Kovasznay B, Schwartz JE. Prevalence and severity of substance use disorders and onset of psychosis in first-admission psychotic patients. Psychol Med 1998;28:1411-9.
129. Swofford CD, Scheller-Gilkey G, Miller AH, Woolwine B, Mance R. Double jeopardy: schizophrenia and substance use. Am J Drug Alcohol Abuse 2000;26:343-53.
130. Moore TH, Zammit S, Lingford-Hughes A, Barnes TR, Jones PB, Burke M, et al. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet 2007;370:319-28.
131. Henquet C, Krabbendam L, Spauwen J, Kaplan C, Lieb R, Wittchen HU, et al. Prospective cohort study of cannabis use, predisposition for psychosis, and psychotic symptoms in young people. BMJ 2005;330:11.
132. McGuire P, Jones P, Harvey I, Williams M, McGuffin P, Murray R. Morbid risk of schizophrenia for relatives of patients with cannabis-associated psychosis. Schizophr Res 1995;15:277-81.
133. Caspi A, Moffitt TE, Cannon M, McClay J, Murray R, Harrington H, et al. Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyl-transferase gene: longitudinal evidence of a gene X environment interaction. Biol Psychiatry 2005;57:1117-27.
134. Henquet C, Rosa A, Krabbendam L, Papiol S, Fananas L, Drukker M, et al. An experimental study of catechol-o-methyltransferase Val158Met moderation of delta-9-tetrahydrocannabinol-induced effects on psychosis and cognition. Neuropsychopharmacology 2006;31:2748-57.
135. Zammit S, Spurlock G, Williams H, Norton N, Williams N, O'Donovan MC, et al. Genotype effects of CHRNA7, CNR1 and COMT in schizophrenia: interactions with tobacco and cannabis use. Br J Psychiatry 2007;191:402-7.
136. Boucher AA, Arnold JC, Duffy L, Schofield PR, Micheau J, Karl T. Heterozygous neuregulin 1 mice are more sensitive to the behavioural effects of delta9-tetrahydrocannabinol. Psychopharmacology (Berl) 2007;192:325-36.
137. Boucher AA, Hunt GE, Karl T, Micheau J, McGregor IS, Arnold JC. Heterozygous neuregulin 1 mice display greater baseline and delta(9)-tetrahydrocannabinol-induced c-Fos expression. Neuroscience 2007;149:861-70.
138. Kishimoto M, Ujike H, Motohashi Y, Tanaka Y, Okahisa Y, Kotaka T, et al. The dysbindin gene (DTNBP1) is associated with methamphetamine psychosis. Biol Psychiatry 2008;63:191-6.
139. Cullberg J. Stressful life events preceding the first onset of psychosis. An explorative study. Nord J Psychiatry 2003;57:209-14.
140. Ventura J, Nuechterlein KH, Subotnik KL, Hardesty JP, Mintz J. Life events can trigger depressive exacerbation in the early course of schizophrenia. J Abnorm Psychol 2000;109:139-44.
141. Myin-Germeys I, Peeters F, Havermans R, Nicolson NA, DeVries MW, Delespaul P, et al. Emotional reactivity to daily life stress in psychosis and affective disorder: an experience sampling study. Acta Psychiatr Scand 2003;107:124-31.
142. Myin-Germeys I, van Os J. Stress-reactivity in psychosis: evidence for an affective pathway to psychosis. Clin Psychol Rev 2007;27:409-24.
143. van Winkel R, Henquet C, Rosa A, Papiol S, Fananás L, De Hert M, et al. Evidence that the COMT(Val158Met) polymorphism moderates sensitivity to stress in psychosis: an experience-sampling study. Am J Med Genet B Neuropsychiatr Genet 2008;147B:10-7.
144. Jones JE. Patterns of transactional style deviance in the TAT's of parents of schizophrenics. Fam Process 1977;16:327-37.
145. Doane JA. Family interaction and communication deviance in disturbed and normal families: a review of research. Fam Process 1978; 17:357-76.
146. Miklowitz DJ, Stackman D. Communication deviance in families of schizophrenic and other psychiatric patients: current state of the construct. Prog Exp Pers Psychopathol Res 1992;15:1-46.
147. Velligan DI, Mahurin RK, Eckert SL, Hazleton BC, Miller A. Relationship between specific types of communication deviance and attentional performance in patients with schizophrenia. Psychiatry Res 1997;70:9-20.
148. Wahlberg KE, Wynne LC, Hakko H, Laksy K, Moring J, Miettunen J, et al. Interaction of genetic risk and adoptive parent communication deviance: longitudinal prediction of adoptee psychiatric disorders. Psychol Med 2004;34:1531-41.
149. Wahlberg KE, Wynne LC, Oja H, Keskitalo P, Pykalainen L, Lahti I, et al. Gene-environment interaction in vulnerability to schizophrenia: findings from the Finnish Adoptive Family Study of schizophrenia. Am J Psychiatry 1997;154:355-62.
150. Subotnik KL, Goldstein MJ, Nuechterlein KH, Woo SM, Mintz J. Are communication deviance and expressed emotion related to family history of psychiatric disorders in schizophrenia? Schizophr Bull 2002;28:719-29.
151. Lau J, Eley T. Gene-environment interactions and correlations in psychiatric disorders. Curr Psychiatry Rep 2004;6:119-24.
152. Phillips LJ, Curry C, Yung AR, Yuen HP, Adlard S, McGorry PD. Cannabis use is not associated with the development of psychosis in an "ultra" high-risk group. Aust N Z J Psychiatry 2002; 36:800-6.
153. Yun Y, Phillips LJ, Cotton S, Yung AR, Francey SM, Yuen HP, et al. Obstetric complications and transition to psychosis in an "ultra" high risk sample. Aust N Z J Psychiatry 2005; 39:460-6.
154. Kendler KS, Eaves LJ. Models for the joint effect of genotype and environment on liability to psychiatric illness. Am J Psychiatry 1986;143:279-89.
155. Patrick G, Straumanis JJ, Struve FA, Fitz-Gerald MJ, Leavitt J, Manno JE. Reduced P50 auditory gating response in psychiatrically normal chronic marihuana users: a pilot study. Biol Psychiatry 1999;45:1307-12.
156. Patrick G, Struve FA. Reduction of auditory P50 gating response in marihuana users: further supporting data. Clin Electroencephalogr 2000;31:88-93.
157. Rentzsch J, Penzhorn A, Kernbichler K, Plockl D, Gomez-Carrillo de Castro A, Gallinat J, et al. Differential impact of heavy cannabis use on sensory gating in schizophrenic patients and otherwise healthy controls. Exp Neurol 2007;205:241-9.
158. Oranje B, Van Oel CJ, Gispen-De Wied CC, Verbaten MN, Kahn RS. Effects of typical and atypical antipsychotics on the prepulse inhibition of the startle reflex in patients with schizophrenia. J Clin Psychopharmacol 2002;22:359-65.
159. Adler LE, Olincy A, Cawthra E, Hoffer M, Nagamoto HT, Amass L, et al. Reversal of diminished inhibitory sensory gating in cocaine addicts by a nicotinic cholinergic mechanism. Neuropsychopharmacology 2001;24:671-9.
160. Broome MR, Johns LC, Valli I, Woolley JB, Tabraham P, Brett C, et al. Delusion formation and reasoning biases in those at clinical high risk for psychosis. Br J Psychiatry 2007;51(Suppl):s38-42.
161. Cameron AM, Oram J, Geffen GM, Kavanagh DJ, McGrath JJ, Geffen LB. Working memory correlates of three symptom clusters in schizophrenia. Psychiatry Res 2002;110:49-61.
162. Daban C, Amado I, Bayle F, Gut A, Willard D, Bourdel MC, et al.
163. Donohoe G, Corvin A, Robertson IH. Evidence that specific executive functions predict symptom variance among schizophrenia patients with a predominantly negative symptom profile. Cognit Neuropsychiatry 2006;11:13-32.
164. Hofer A, Baumgartner S, Bodner T, Edlinger M, Hummer M, Kemmler G, et al. Patient outcomes in schizophrenia II: the impact of cognition. Eur Psychiatry 2005;20:395-402.
165. Martinez-Aran A, Penades R, Vieta E, Colom F, Reinares M, Benabarre A, et al. Executive function in patients with remitted bipolar disorder and schizophrenia and its relationship with functional outcome. Psychother Psychosom 2002;71:39-46.
166. Milev P, Ho BC, Arndt S, Andreasen NC. Predictive values of neurocognition and negative symptoms on functional outcome in schizophrenia: a longitudinal first-episode study with 7-year follow-up. Am J Psychiatry 2005;162:495-506.
167. Prouteau A, Verdoux H, Briand C, Lesage A, Lalonde P, Nicole L, et al. Cognitive predictors of psychosocial functioning outcome in schizophrenia: a follow-up study of subjects participating in a rehabilitation program. Schizophr Res 2005;77:343-53.
168. Stirling J, White C, Lewis S, Hopkins R, Tantam D, Huddy A, et al. Neurocognitive function and outcome in first-episode schizophrenia: a 10-year follow-up of an epidemiological cohort. Schizophr Res 2003;65:75-86.
169. Green MF, Kern RS, Heaton RK. Longitudinal studies of cognition and functional outcome in schizophrenia: implications for MATRICS. Schizophr Res 2004;72:41-51.
170. Peuskens J, Demily C, Thibaut F. Treatment of cognitive dysfunction in schizophrenia. Clin Ther 2005;27(Suppl A):S25-37.
171. Kasper S, Resinger E. Cognitive effects and antipsychotic treatment. Psychoneuroendocrinology 2003;28(Suppl 1):27-38.
172. Weiss EM, Bilder RM, Fleischhacker WW. The effects of second-generation antipsychotics on cognitive functioning and psychosocial outcome in schizophrenia. Psychopharmacology 2002;162:11-7.
173. Woodward N, Purdon S, Meltzer H, Zald D. A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. Int J Neuropsychopharmacol 2005;8:457-72.
174. Green M. Cognitive remediation in schizophrenia: is it time yet? Am J Psychiatry 1993;150:178-87.
175. McGurk SR, Twamley EW, Sitzer DI, McHugo GJ, Mueser KT. A meta-analysis of cognitive remediation in schizophrenia. Am J Psychiatry 2007;164:1791-802.
176. Pilling S, Bebbington P, Kuipers E, Garety P, Geddes J, Martindale B, et al. Psychological treatments in schizophrenia: II. Meta-analyses of randomized controlled trials of social skills training and cognitive remediation. Psychol Med 2002;32:783-91.
177. Honey GD, Fletcher PC. Investigating principles of human brain function underlying working memory: what insights from schizophrenia? Neuroscience 2006;139:59-71.
178. Pukrop R, Matuschek E, Ruhrmann S, Brockhaus-Dumke A, Tendolkar I, Bertsch A, et al. Dimensions of working memory dysfunction in schizophrenia. Schizophr Res 2003;62:259-68.
179. Arranz MJ, Munro J, Osborne S, Collier D, Kerwin RW. Applications of pharmacogenetics in psychiatry: personalisation of treatment. Expert Opin Pharmacother 2001;2:537-42.
180. Woodward ND, Jayathilake K, Meltzer HY. COMT val108/158met genotype, cognitive function, and cognitive improvement with clozapine in schizophrenia. Schizophr Res 2007;90:86-96.
181. Bosia M, Bechi M, Marino E, Anselmetti S, Poletti S, Cocchi F, et al. Influence of catechol-O-methyltransferase Val158Met polymorphism on neuropsychological and functional outcomes of classical rehabilitation and cognitive remediation in schizophrenia. Neurosci Lett 2007;417:271-4.
182. Harrison PJ, Owen MJ. Genes for schizophrenia? Recent findings and their pathophysiological implications. Lancet 2003;361:417-9.
183. Li T, Stefansson H, Gudfinnsson E, Cai G, Liu X, Murray RM, et al. Identification of a novel neuregulin 1 at-risk haplotype in Han schizophrenia Chinese patients, but no association with the Icelandic/ Scottish risk haplotype. Mol Psychiatry 2004;9:698-704.
184. Hong CJ, Huo SJ, Liao DL, Lee K, Wu JY, Tsai SJ. Case-control and family-based association studies between the neuregulin 1 (Arg38GIn) polymorphism and schizophrenia. Neurosci Lett 2004;366:158-61.
185. Thiselton DL, Webb BT, Neale BM, Ribble RC, O'Neill FA, Walsh D, et al. No evidence for linkage or association of neuregulin-1 (NRG 1) with disease in the Irish study of high-density schizophrenia families (ISHDSF). Mol Psychiatry 2004;9:777-83.
186. Hall D, Gogos JA, Karayiorgou M. The contribution of three strong candidate schizophrenia susceptibility genes in demographically distinct populations. Genes Brain Behav 2004;3:240-8.
187. Stefansson H, Sarginson J, Kong A, Yates P, Steinthorsdottir V, Gudfinnsson E, et al. Association of neuregulin 1 with schizophrenia confirmed in a Scottish population. Am J Hum Genet 2003;72:83-7.
188. Stefansson H, Sigurdsson E, Steinthorsdottir V, Bjornsdottir S, Sigmundsson T, Ghosh S, et al. Neuregulin 1 and susceptibility to schizophrenia. Am J Hum Genet 2002;71:877-92.
189. Ingason A, Soeby K, Timm S, Wang AG, Jakobsen KD, Fink-Jensen A, et al. No significant association of the 5′ end of neuregulin 1 and schizophrenia in a large Danish sample. Schizophr Res 2006;83:1-5.
190. Walss-Bass C, Raventos H, Montero AP, Armas R, Dassori A, Contreras S, et al. Association analyses of the neuregulin 1 gene with schizophrenia and manic psychosis in a Hispanic population. Acta Psychiatr Scand 2006;113:314-21.
191. Yang JZ, Si TM, Ruan Y, Ling YS, Han YH, Wang XL, et al. Association study of neuregulin 1 gene with schizophrenia. Mol Psychiatry 2003;8:706-9.
192. Petryshen TL, Middleton FA, Kirby A, Aldinger KA, Purcell S, Tahl AR, et al. Support for involvement of neuregulin 1 in schizophrenia pathophysiology. Mol Psychiatry 2005;10:366-74.
193. Liu CM, Hwu HG, Fann CS, Lin CY, Liu YL, Ou-Yang WC, et al. Linkage evidence of schizophrenia to loci near neuregulin 1 gene on chromosome 8p21 in Taiwanese families. Am J Med Genet B Neuropsychiatr Genet 2005;134:79-83.
194. Kim JW, Lee YS, Cho EY, Jang YL, Park DY, Choi KS, et al. Linkage and association of schizophrenia with genetic variations in the locus of neuregulin 1 in Korean population. Am J Med Genet B Neuropsychiatr Genet 2006;141:281-6.
195. McGuffin P, Rijsdijk F, Andrew M, Sham P, Katz R, Cardno A. The heritability of bipolar affective disorder and the genetic relationship to unipolar depression. Arch Gen Psychiatry 2003;60:497-502.
196. Liu YL, Fann CS, Liu CM, Chang CC, Wu JY, Hung SI, et al. No association of G72 and D-amino acid oxidase genes with schizophrenia. Schizophr Res 2006;87:15-20.
197. Hattori E, Liu C, Badner JA, Bonner TI, Christian SL, Maheshwari M, et al. Polymorphisms at the G72/G30 gene locus, on 13q33, are associated with bipolar disorder in two independent pedigree series. Am J Hum Genet 2003;72:1131-40.
198. Shin HD, Park BL, Kim EM, Lee SO, Cheong HS, Lee CH, et al. Association analysis of G72/G30 polymorphisms with schizophrenia in the Korean population. Schizophr Res 2007;96:119-24.
199. Williams HJ, Williams N, Spurlock G, Norton N, Zammit S, Kirov G, et al. Detailed analysis of PRODH and PsPRODH reveals no association with schizophrenia. Am J Med Genet 2003;120B:42-6.
200. Chumakov I, Blumenfeld M, Guerassimenko O, Cavarec L, Palicio M, Abderrahim H, et al. Genetic and physiological data implicating the new human gene G72 and the gene for D-amino acid oxidase in schizophrenia. Proc Natl Acad Sci USA 2002;99:13675-80.
201. Wang X, He G, Gu N, Yang J, Tang J, Chen Q, et al. Association of G72/ G30 with schizophrenia in the Chinese population. Biochem Biophys Res Commun 2004;319:1281-6.
202. Korostishevsky M, Kaganovich M, Cholostoy A, Ashkenazi M, Ratner Y, Dahary D, et al. Is the G72/G30 locus associated with schizophrenia? single nucleotide polymorphisms, haplotypes, and gene expression analysis. Biol Psychiatry 2004;56:169-76.
203. Ma J, Qin W, Wang XY, Guo TW, Bian L, Duan SW, et al. Further evidence for the association between G72/G30 genes and schizophrenia in two ethnically distinct populations. Mol Psychiatry 2006;11:479-87.
204. Yue W, Liu Z, Kang G, Yan J, Tang F, Ruan Y, et al. Association of G72/G30 polymorphisms with early-onset and male schizophrenia. Neuroreport 2006;17:1899-902.
205. Shinkai T, De Luca V, Hwang R, Muller DJ, Lanktree M, Zai G, et al. Association analyses of the DAOA/G30 and D-amino-acid oxidase genes in schizophrenia: further evidence for a role in schizophrenia. Neuromolecular Med 2007;9:169-77.
206. Austin CP, Ma L, Ky B, Morris JA, Shughrue PJ. DISC1 (Disrupted in Schizophrenia-1) is expressed in limbic regions of the primate brain. Neuroreport 2003;14:951-4.
207. Devon RS, Anderson S, Teague PW, Burgess P, Kipari TM, Semple CA, et al. Identification of polymorphisms within Disrupted in Schizophrenia 1 and Disrupted in Schizophrenia 2, and an investigation of their association with schizophrenia and bipolar affective disorder. Psychiatr Genet 2001;11:71-8.
208. Ozeki Y, Tomoda T, Kleiderlein J, Kamiya A, Bord L, Fujii K, et al. Disrupted-in-Schizophrenia-I (DISC-1): mutant truncation prevents binding to NudE-like (NUDEL) and inhibits neurite outgrowth. Proc Natl Acad Sci USA 2003;100:289-94.
209. Kockelkorn TT, Arai M, Matsumoto H, Fukuda N, Yamada K, Minabe Y, et al. Association study of polymorphisms in the 5′ upstream region of human DISC1 gene with schizophrenia. Neurosci Lett 2004;368:41-5.
210. Ma L, Liu Y, Ky B, Shughrue PJ, Austin CP, Morris JA. Cloning and characterization of Disc 1, the mouse ortholog of DISC1 (Disrupted-in-Schizophrenia 1). Genomics 2002;80:662-72.
211. Ekelund J, Hovatta I, Parker A, Paunio T, Varilo T, Martin R, et al. Chromosome 1 loci in Finnish schizophrenia families. Hum Mol Genet 2001;10:1611-7.
212. Zhang X, Tochigi M, Ohashi J, Maeda K, Kato T, Okazaki Y, et al. Association study of the DISC1/TRAX locus with schizophrenia in a Japanese population. Schizophr Res 2005;79:175-80.
213. Blackwood DH, Fordyce A, Walker MT, St Clair DM, Porteous DJ, Muir WJ. Schizophrenia and affective disorders - cosegregation with a translocation at chromosome 1q42 that directly disrupts brain-expressed genes: clinical and P300 findings in a family. Am J Hum Genet 2001;69:428-33.
214. Kato T. Molecular genetics of bipolar disorder. Neurosci Res 2001;40:105-13.
215. Millar JK, Christie S, Anderson S, Lawson D, Hsiao-Wei Loh D, Devon RS, et al. Genomic structure and localisation within a linkage hotspot of Disrupted In Schizophrenia 1, a gene disrupted by a translocation segregating with schizophrenia. Mol Psychiatry 2001;6:173-8.
216. Millar JK, Christie S, Semple CA, Porteous DJ. Chromosomal location and genomic structure of the human translin-associated factor X gene (TRAX; TSNAX) revealed by intergenic splicing to DISC1, a gene disrupted by a translocation segregating with schizophrenia. Genomics 2000;67:69-77.
217. Millar JK, Wilson-Annan JC, Anderson S, Christie S, Taylor MS, Semple CA, et al. Disruption of two novel genes by a translocation co-segregating with schizophrenia. Hum Mol Genet 2000;9:1415-23.
218. Hodgkinson CA, Goldman D, Jaeger J, Persaud S, Kane JM, Lipsky RH, et al. Disrupted in schizophrenia I (DISC1): association with schizophrenia, schizoaffective disorder, and bipolar disorder. Am J Hum Genet 2004;75:862-72.
219. Zhang F, Sarginson J, Crombie C, Walker N, St Clair D, Shaw D. Genetic association between schizophrenia and the DISC1 gene in the Scottish population. Am J Med Genet B Neuropsychiatr Genet 2006;141:155-9.
220. Chen QY, Chen Q, Feng GY, Lindpaintner K, Wang LJ, Chen ZX, et al. Case-control association study of Disrupted-in-Schizophrenia-1 (DISC1) gene and schizophrenia in the Chinese population. J Psychiatr Res 2007;41:428-34.
221. Qian L, Zhao J, Shi Y, Zhao X, Feng G, Xu F, et al. Brain-derived neurotrophic factor and risk of schizophrenia: an association study and meta-analysis. Biochem Biophys Res Commun 2007;353:738-43.
222. Numata S, Ueno S, Iga J, Yamauchi K, Hongwei S, Ohta K, et al. Brain-derived neurotrophic factor (BDNF) Va166Met polymorphism in schizophrenia is associated with age at onset and symptoms. Neurosci Lett 2006;401:1-5.
223. Shimizu E, Hashimoto K, Watanabe H, Komatsu N, Okamura N, Koike K, et al. Serum brain-derived neurotrophic factor (BDNF) levels in schizophrenia are indistinguishable from controls. Neurosci Lett 2003;351:111-4.
224. Skibinska M, Hauser J, Czerski PM, Leszczynska-Rodziewicz A, Kosmowska M, Kapelski P, et al. Association analysis of brain-derived neurotrophic factor (BDNF) gene Val66Met polymorphism in schizophrenia and bipolar affective disorder. World J Biol Psychiatry 2004; 5:215-20.
225. Rosa A, Cuesta MJ, Fatjo-Vilas M, Peralta V, Zarzuela A, Fananas L. The Val66Met polymorphism of the brain-derived neurotrophic factor gene is associated with risk for psychosis: evidence from a family-based association study. Am J Med Genet B Neuropsychiatr Genet 2006;141:135-8.
226. Neves-Pereira M, Cheung JK, Pasdar A, Zhang F, Breen G, Yates P, et al. BDNF gene is a risk factor for schizophrenia in a Scottish population. Mol Psychiatry 2005;10:208-12.
227. Galderisi S, Maj M, Kirkpatrick B, Piccardi P, Mucci A, Invernizzi G, et al. COMT Val(158)Met and BDNF C(270)T polymorphisms in schizophrenia: a case-control study. Schizophr Res 2005;73:27-30.
228. Hong CJ, Yu YW, Lin CH, Tsai SJ. An association study of a brain-derived neurotrophic factor Va166Met polymorphism and clozapine response of schizophrenic patients. Neurosci Lett 2003;349:206-8.
229. Iritani S, Niizato K, Nawa H, Ikeda K, Emson PC. Immunohistochemical study of brain-derived neurotrophic factor and its receptor, TrkB, in the hippocampal formation of schizophrenic brains. Prog Neuropsychopharmacol Biol Psychiatry 2003;27:801-7.
230. Szczepankiewicz A, Skibinska M, Czerski PM, Kapelski P, Leszczynska-Rodziewicz A, Slopien A, et al. No association of the brain-derived neurotrophic factor (BDNF) gene C-270T polymorphism with schizophrenia. Schizophr Res 2005;76:187-93.
231. Nawa H, Futamura T, Mizuno M, Takahashi M, Toyooka K, Someya T. Contribution of neurotrophic factors and cytokinese to schizophrenia. Nippon Rinsho 2003;61:521-8.
232. Chen QY, Chen Q, Feng GY, Wan CL, Lindpaintner K, Wang LJ, et al. Association between the brain-derived neurotrophic factor (BDNF) gene and schizophrenia in the Chinese population. Neurosci Lett 2006;397:285-90.
233. Seidman LJ, Wencel HE. Genetically mediated brain abnormalities in schizophrenia. Curr Psychiatry Rep 2003;5:135-44.
234. Tochigi M, Otowa T, Suga M, Rogers M, Minato T, Yamasue H, et al. No evidence for an association between the BDNF Val66Met polymorphism and schizophrenia or personality traits. Schizophr Res 2006;87:45-7.
235. Molnar M, Potkin SG, Bunney WE, Jones EG. MRNA expression patterns and distribution of white matter neurons in dorsolateral prefrontal cortex of depressed patients differ from those in schizophrenia patients. Biol Psychiatry 2003;53:39-47.
236. Naoe Y, Shinkai T, Hori H, Fukunaka Y, Utsunomiya K, Sakata S, et al. No association between the brain-derived neurotrophic factor (BDNF) Val66Met polymorphism and schizophrenia in Asian populations: Evidence from a case-control study and meta-analysis. Neurosci Lett 2007;415:108-12.
237. Szekeres G, Juhasz A, Rimanoczy A, Keri S, Janka Z. The C270T polymorphism of the brain-derived neurotrophic factor gene is associated with schizophrenia. Schizophr Res 2003;65:15-8.
238. Duan J, Martinez M, Sanders AR, Hou C, Burrell GJ, Krasner AJ, et al. DTNBP1 (Dystrobrevin binding protein 1) and schizophrenia: association evidence in the 3′ end of the gene. Hum Hered 2007;64:97-106.
239. Mutsuddi M, Morris DW, Waggoner SG, Daly MJ, Scolnick EM, Sklar P. Analysis of high-resolution Hap-Map of DTNBP1 (Dysbindin) suggests no consistency between reported common variant associations and schizophrenia. Am J Hum Genet 2006;79:903-9.
240. Vilella E, Costas J, Sanjuan J, Guitart M, De Diego Y, Carracedo A, et al. Association of schizophrenia with DTNBP1 but not with DAO, DAOA, NRG1 and RGS4 nor their genetic interaction. J Psychiatr Res 2008;42:278-88.
241. Morris DW, McGhee KA, Schwaiger S, Scully P, Quinn J, Meagher D, et al. No evidence for association of the dysbindin gene. Schizophr Res 2003;60:167-72.
242. Tochigi M, Zhang X, Ohashi J, Hibino H, Otowa T, Rogers M, et al. Association study of the dysbindin (DTNBP1) gene in schizophrenia from the Japanese population. Neurosci Res 2006;56:154-8.
243. Fanous AH, van den Oord EJ, Riley BP, Aggen SH, Neale MC, O'Neill FA, et al. Relationship between a high-risk haplotype in the DTNBP1 (dysbindin) gene and clinical features of schizophrenia. Am J Psychiatry 2005;162:1824-32.
244. Straub RE, Jiang Y, MacLean CJ, Ma Y, Webb BT, Myakishev MV, et al. Genetic variation in the 6p22.3 gene DTNBP1, the human ortholog of the mouse dysbindin gene, is associated with schizophrenia. Am J Hum Genet 2002;71:337-48.
245. McGuffin P, Tandon K, Corsico A. Linkage and association studies of schizophrenia. Curr Psychiatry Rep 2003;5:121-7.
246. Schwab SG, Knapp M, Mondabon S, Hallmayer J, Borrmann-Hassenbach M, Albus M, et al. Support for association of schizophrenia with genetic variation in the 6p22.3 gene, dysbindin, in sib-pair families with linkage and in an additional sample of triad families. Am J Hum Genet 2003;72:1 85-90.
247. Van Den Bogaert A, Schumacher J, Schulze TG, Otte AC, Ohlraun S, Kovalenko S, et al. The DTNBP1 (dysbindin) gene contributes to schizophrenia, depending on family history of the disease. Am J Hum Genet 2003;73:1438-43.
248. Luo X, Klempan TA, Lappalainen J, Rosenheck RA, Charney DS, Erdos J, et al. NOTCH4 gene haplotype is associated with schizophrenia in African Americans. Biol Psychiatry 2004;55:112-7.
249. Tochigi M, Zhang X, Umekage T, Ohashi J, Kato C, Marui T, et al. Association of six polymorphisms of the NOTCH4 gene with schizophrenia in the Japanese population. Am J Med Genet B Neuropsychiatr Genet 2004;128:37-40.
250. Anttila S, Kampman O, Illi A, Roivas M, Mattila KM, Lassila V, et al. NOTCH4 gene promoter polymorphism is associated with the age of onset in schizophrenia. Psychiatr Genet 2003;13:61-4.
251. Shibata N, Ohnuma T, Higashi S, Higashi M, Usui C, Ohkubo T, et al. Genetic association between Notch4 polymorphisms and Japanese schizophrenics. Psychiatr Genet 2006;1 6:77-9.
252. Tazi-Ahnini R, Timms JM, Cox A, Wilson AG. Identification of novel single nucleotide polymorphisms within the NOTCH4 gene and determination of association with MHC alleles. Eur J Immunogenet 2003;30:101-5.
253. Takahashi S, Cui YH, Kojima T, Han YH, Yu SY, Tanabe E, et al. Family-based association study of the NOTCH4 gene in schizophrenia using Japanese and Chinese samples. Biol Psychiatry 2003;54:129-35.
254. Skol AD, Young KA, Tsuang DW, Faraone SV, Haverstock SL, Bingham S, et al. Modest evidence for linkage and possible confirmation of association between NOTCH4 and schizophrenia in a large Veterans Affairs Cooperative Study sample. Am J Med Genet 2003;118B:8-15.
255. Carmine A, Chheda MG, Jonsson EG, Sedvall GC, Farde L, Gustavsson JP, et al. Two NOTCH4 polymorphisms and their relation to schizophrenia susceptibility and different personality traits. Psychiatr Genet 2003;13:23-8.
256. Wassink TH, Nopoulos P, Pietila J, Crowe RR, Andreasen NC. NOTCH4 and the frontal lobe in schizophrenia. Am J Med Genet 2003;118B:1-7.
257. Swift-Scanlan T, Lan TH, Fallin MD, Coughlin JM, Potash JB, De Paulo JR, et al. Genetic analysis of the (CTG)n NOTCH4 polymorphism in 65 multiplex bipolar pedigrees. Psychiatr Genet 2002;12:43-7.
258. McGinnis RE, Fox H, Yates P, Cameron LA, Barnes MR, Gray IC, et al. Failure to confirm NOTCH4 association with schizophrenia in a large population-based sample from Scotland. Nat Genet 2001;28:128-9.
259. Fan JB, Tang JX, Gu NF, Feng GY, Zou FG, Xing YL, et al. A family-based and case-control association study of the NOTCH4 gene and schizophrenia. Mol Psychiatry 2002;7:100-3.
260. Wei J, Hemmings GP. The NOTCH4 Locus is associated with susceptibility to schizophrenia. Nat Genet 2000;25:376-7.
261. Sklar P, Schwab SG, Williams NM, Daly M, Schaffner S, Maier W, et al. Association analysis of NOTCH4 loci in schizophrenia using family and population-based controls. Nat Genet 2001;28:126-8.
262. Ujike H, Takehisa Y, Takaki M, Tanaka Y, Nakata K, Takeda T, et al. NOTCH4 gene polymorphism and susceptibility to schizophrenia and schizoaffective disorder. Neurosci Lett 2001;301:41-4.
263. Fujii Y, Shibata H, Kikuta R, Makino C, Tani A, Hirata N, et al. Positive associations of polymorphisms in the metabotropic glutamate receptor type 3 gene (GRM3) with schizophrenia. Psychiatr Genet 2003;13:71-6.
264. Norton N, Williams HJ, Dwyer S, Ivanov D, Preece AC, Gerrish A, et al. No evidence for association between polymorphisms in GRM3 and schizophrenia. BMC Psychiatry 2005;5:23.
265. Chen Q, He G, Wu S, Xu Y, Feng G, Li Y, et al. A case-control study of the relationship between the metabotropic glutamate receptor 3 gene and schizophrenia in the Chinese population. Schizophr Res 2005;73:21-6.
266. Tochigi M, Suga M, Ohashi J, Otowa T, Yamasue H, Kasai K, et al. No association between the metabotropic glutamate receptor type 3 gene (GRM3) and schizophrenia in a Japanese population. Schizophr Res 2006b;88:260-4.
267. Bishop JR, Wang K, Moline J, Ellingrod VL. Association analysis of the metabotropic glutamate receptor type 3 gene (GRM3) with schizophrenia. Psychiatr Genet 2007;1 7:358.
268. Albalushi T, Horiuchi Y, Ishiguro H, Koga M, Inada T, Iwata N, et al. Replication study and meta-analysis of the genetic association of GRM3 gene polymorphisms with schizophrenia in a large Japanese case-control population. Am J Med Genet B Neuropsychiatr Genet 2008;147:392-6.
269. Schwab SG, Plummer C, Albus M, Borrmann-Hassenbach M, Lerer B, Trixler M, et al. DNA sequence variants in the metabotropic glutamate receptor 3 and risk to schizophrenia: an association study. Psychiatr Genet 2008;18:25-30.
270. Sugaya K. Neuroreplacement therapy and stem cell biology under disease conditions. Cell Mol Life Sci 2003;60:1891-902.
271. Akahane A, Kunugi H, Tanaka H, Nanko S. Association analysis of polymorphic CGG repeat in 5′ UTR of the reelin and VLDLR genes with schizophrenia. Schizophr Res 2002;58:37-41.
272. Scherk H, Vogeley K, Falkai P. The importance of interneurons in schizophrenic and affective disorders. Fortschr Neurol Psychiatr 2003;71(Suppl 1):S27-32.
273. Knable MB, Torrey EF, Webster MJ, Bartko JJ. Multivariate analysis of prefrontal cortical data from the Stanley Foundation Neuropathology Consortium. Brain Res Bull 2001;55:651-9.
274. Eastwood SL, Law AJ, Everall IP, Harrison PJ. The axonal chemorepellant semaphorin 3A is increased in the cerebellum in schizophrenia and may contribute to its synaptic pathology. Mol Psychiatry 2003;8:148-55.
275. Chen Y, Sharma RP, Costa RH, Costa E, Grayson DR. On the epigenetic regulation of the human reelin promoter. Nucleic Acids Res 2002;30:2930-9.
276. Costa E, Davis J, Pesold C, Tueting P, Guidotti A. The heterozygote reeler mouse as a model for the development of a new generation of antipsychotics. Curr Opin Pharmacol 2002;2:56-62.
277. Fatemi SH, Kroll JL, Stary JM. Altered levels of reelin and its isoforms in schizophrenia and mood disorders. Neuroreport 2001;12:3209-15.
278. Costa E, Davis J, Grayson DR, Guidotti A, Pappas GD, Pesold C. Dendritic spine hypoplasticity and down-regulation of reelin and GABAergic tone in schizophrenia vulnerability. Neurobiol Dis 2001;8:723-42.
279. Fatemi SH, Earle JA, McMenomy T. Reduction in reelin immunoreactivity in hippocampus of subjects with schizophrenia, bipolar disorder and major depression. Mol Psychiatry 2000;5:654-63.
280. Guidotti A, Auta J, Davis JM, Di-Giorgi-Gerevini V, Dwivedi Y, Grayson DR, et al. Decrease in reelin and glutamic acid decarboxylase67 (GAD67) expression in schizophrenia and bipolar disorder: a postmortem brain study. Arch Gen Psychiatry 2000;57:1061-9.
281. Guidotti A, Pesold C, Costa E. New neurochemical markers for psychosis: a working hypothesis of their operation. Neurochem Res 2000;25:1207-18.
282. Rodriguez MA, Pesold C, Liu WS, Kriho V, Guidotti A, Pappas GD, et al. Colocalization of integrin receptors and reelin in dendritic spine postsynaptic densities of adult nonhuman primate cortex. Proc Natl Acad Sci USA 2000;97:3550-5.
283. Goldberg TE, Egan MF, Gscheidle T, Coppola R, Weickert T, Kolachana BS, et al. Executive subprocesses in working memory: relationship to catechol-O-methyltransferase Val158Met genotype and schizophrenia. Arch Gen Psychiatry 2003;60:889-96.
284. Herken H, Erdal ME, Boke O, Savas HA. Tardive dyskinesia is not associated with the polymorphisms of 5-HT2A receptor gene, serotonin transporter gene and catechol-o-methyltransferase gene. Eur Psychiatry 2003;18:77-81.
285. Bray NJ, Buckland PR, Williams NM, Williams HJ, Norton N, Owen MJ, et al. A haplotype implicated in schizophrenia susceptibility is associated with reduced COMT expression in human brain. Am J Hum Genet 2003;73:152-61.
286. Zhang ML, Yuan GZ, Yao JJ, Qian YC, Zhang X, Huang YP, et al. Associations between six functional genes and schizophrenia. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 2003;20:69-71.
287. Matsumoto M, Weickert CS, Beltaifa S, Kolachana B, Chen J, Hyde TM, et al. Catechol O-methyltransferase (COMT) mRNA expression in the dorsolateral prefrontal cortex of patients with schizophrenia. Neuropsychopharmacology 2003;28:1521-30.
288. Rybakowski JK, Borkowska A, Czerski PM, Hauser J. Eye movement disturbances in schizophrenia and a polymorphism of catechol-O-methyltransferase gene. Psychiatry Res 2002;113:49-57.
289. Illi A, Kampman O, Anttila S, Roivas M, Mattila KM, Lehtimaki T, et al. Interaction between angiotensin-converting enzyme and catechol-O-methyltransferase genotypes in schizophrenics with poor response to conventional neuroleptics. Eur Neuropsychopharmacol 2003;13:147-51.
290. Bilder RM, Volavka J, Czobor P, Malhotra AK, Kennedy JL, Ni X, et al. Neurocognitive correlates of the COMT Val(158)Met polymorphism in chronic schizophrenia. Biol Psychiatry 2002;52:701-7.
291. Hariri AR, Weinberger DR. Imaging genomics. Br Med Bull 2003;65:259-70.
292. Park TW, Yoon KS, Kim JH, Park WY, Hirvonen A, Kang D. Functional catechol-O-methyltransferase gene polymorphism and susceptibility to schizophrenia. Eur Neuropsychopharmacol 2002;12:299-303.
293. Weinberger DR, Egan MF, Bertolino A, Callicott JH, Mattay VS, Lipska BK, et al. Prefrontal neurons and the genetics of schizophrenia. Biol Psychiatry 2001;50:825-44.
294. Callicott JH, Egan MF, Mattay VS, Bertolino A, Bone AD, Verchinksi B, et al. Abnormal fMRI response of the dorsolateral prefrontal cortex in cognitively intact siblings of patients with schizophrenia. Am J Psychiatry 2003;160:709-19.
295. Akil M, Kolachana BS, Rothmond DA, Hyde TM, Weinberger DR, Kleinman JE. Catechol-O-methyltransferase genotype and dopamine regulation in the human brain. J Neurosci 2003;23:2008-13.
296. Owen MJ, Williams NM, O'Donovan MC. The molecular genetics of schizophrenia: new findings promise new insights. Mol Psychiatry 2004;9:14-27.
297. Tsai SJ, Yu YW, Chen TJ, Chen JY, Liou YJ, Chen MC, et al. Association study of a functional catechol-O-methyltransferase-gene polymorphism and cognitive function in healthy females. Neurosci Lett 2003;338:123-6.
298. Semwal P, Prasad S, Varma PG, Bhagwat AM, Deshpande SN, Thelma BK. Candidate gene polymorphisms among North Indians and their association with schizophrenia in a case-control study. J Genet 2002;81:65-71.
299. Shifman S, Bronstein M, Sternfeld M, Pisante-Shalom A, Lev-Lehman E, Weizman A, et al. A highly significant association between a COMT haplotype and schizophrenia. Am J Hum Genet 2002;71:1296-302.
300. Schumacher J, Cichon S, Rietschel M, Nothen MM, Propping P. Genetics of bipolar affective disorders. Current status of research for identification of susceptibility genes. Nervenarzt 2002;73:581-92.
301. Norton N, Kirov G, Zammit S, Jones G, Jones S, Owen R, et al. Schizophrenia and functional polymorphisms in the MAOA and COMT genes: no evidence for association or epistasis. Am J Med Genet 2002;114:491-6.
302. Huber JC, Schneeberger C, Tempfer CB. Genetic modelling of the estrogen metabolism as a risk factor of hormone-dependent disorders. Maturitas 2002;42:1-12.
303. Chowdari KV, Mirnics K, Semwal P, Wood J, Lawrence E, Bhatia T, et al. Association and linkage analyses of RGS4 polymorphisms in schizophrenia. Hum Mol Genet 2002;11:1373-80.
304. Mirnics K, Middleton FA, Stanwood GD, Lewis DA, Levitt P. Disease-specific changes in regulator of G-protein signaling 4 (RGS4) expression in schizophrenia. Mol Psychiatry 2001;6:293-301.
305. Fan JB, Ma J, Zhang CS, Tang JX, Gu NF, Feng GY, et al. A family-based association study of T1945C polymorphism in the proline dehydrogenase gene and schizophrenia in the Chinese population. Neurosci Lett 2003;338:252-4.
306. Lee YH, Nadaraia S, Gu D, Becker DF, Tanner JJ. Structure of the proline dehydrogenase domain of the multifunctional PutA flavoprotein. Nat Struct Biol 2003;10:109-14.
307. Jacquet H, Raux G, Thibaut F, Hecketsweiler B, Houy E, Demilly C, et al. PRODH mutations and hyperprolinemia in a subset of schizophrenic patients. Hum Mol Genet 2002;11:2243-9.
308. Williams M. Genome-based drug discovery: prioritizing disease-susceptibility/disease-associated genes as novel drug targets for schizophrenia. Curr Opin Investig Drugs 2003;4:31-6.
309. De Luca V, Wong AH, Muller DJ, Wong GW, Tyndale RF, Kennedy JL. Evidence of association between smoking and alpha-7 nicotinic receptor subunit gene in schizophrenia patients. Neuropsychopharmacology 2004;29:1522-6.
310. Freedman R, Leonard S, Gault JM, Hopkins J, Cloninger CR, Kaufmann CA, et al. Linkage disequilibrium for schizophrenia at the chromosome 15q13-14 locus of the alpha7-nicotinic acetylcholine receptor subunit gene (CHRNA7). Am J Med Genet 2001;105:20-2.
311. Xu J, Pato MT, Torre CD, Medeiros H, Carvalho C, Basile VS, et al. Evidence for linkage disequilibrium between the alpha-7 nicotinic receptor gene (CHRNA7) locus and schizophrenia in Azorean families. Am J Med Genet 2001;105:669-74.
312. Riley BP, Makoff A, Mogudi-Carter M, Jenkins T, Williamson R, Collier D, et al. Haplotype transmission disequilibrium and evidence for linkage of the CHRNA7 gene region to schizophrenia in Southern African Bantu families. Am J Med Genet 2000;96:196-201.
313. Freedman R, Adler LE, Bickford P, Byerley W, Coon H, Cullum CM, et al. Schizophrenia and nicotinic receptors. Harv Rev Psychiatry 1994;2:179-92.
314. Iwata Y, Nakajima M, Yamada K, Nakamura K, Sekine Y, Tsuchiya KJ, et al. Linkage disequilibrium analysis of the CHRNA7 gene and its partially duplicated region in schizophrenia. Neurosci Res 2007;57:194-202.
315. Fan JB, Ma J, Li XW, Zhang CS, Sun WW, He G, et al. Population-based and family-based association studies of an (AC)n dinucleotide repeat in alpha-7 nicotinic receptor subunit gene and schizophrenia. Schizophr Res 2006;84:222-7.
316. Neves-Pereira M, Bassett AS, Honer WG, Lang D, King NA, Kennedy JL. No evidence for linkage of the CHRNA7 gene region in Canadian schizophrenia families. Am J Med Genet 1998;81:361-3.